Format

Send to

Choose Destination
Neurobiol Dis. 2010 Oct;40(1):216-21. doi: 10.1016/j.nbd.2010.05.028. Epub 2010 May 31.

Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study.

Author information

1
MRC Clinical Sciences Centre and Centre for Neuroscience, Faculty of Medicine, Hammersmith Hospital, Imperial College London, UK. marios.politis@imperial.ac.uk

Abstract

Thirty Parkinson's disease (PD) patients were divided into three equal groups according to their disease duration while 10 normal healthy volunteers matched for age and sex served as a control group. Striatal and extrastriatal serotonergic function was studied with (11)C-DASB PET, a marker of serotonin transporter availability. (11)C-DASB binding was correlated with disease disability and exposure to dopaminergic therapy. We found significant (11)C-DASB binding reductions in striatal, brainstem, and cortical regions in PD but no correlations were evident between (11)C-DASB binding and UPDRS scores, Hoehn &Yahr staging, disease duration and level of exposure to dopaminergic therapy. Our results suggest that progressive non-linear serotonergic dysfunction occurs in PD but it does not determine levels of disability. Additionally, chronic exposure to dopaminergic therapy does not appear to influence SERT binding.

PMID:
20594979
DOI:
10.1016/j.nbd.2010.05.028
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center